Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study.

No Thumbnail Available
Date
2003-06-26
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
A liposomal amphotericin B preparation (L-AMP-LRC-1) has been developed and tested successfully in adults by us. This preparation was administered to 23 neonates with candidiasis in an open phase II study. All the 14 assessable patients responded completely to the L-AMP-LRC-1 therapy given at 1 mg/kg for 28 days. Compared to AmBisome, another liposomal formulation of amphotericin B, L-AMP-LRC-1 was effective at lower dose in neonatal candidiasis. Thus L-AMP-LRC-1 appears to be an effective and low cost drug for the treatment of candidiasis.
Description
Keywords
Citation
Kotwani RN, Bodhe PV, Kirodian BG, Mehta KP, Ali US, Kshirsagar NA. Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study. Indian Pediatrics. 2003 Jun; 40(6): 545-50
URI
https://imsear.searo.who.int/handle/123456789/7977
Collections
Indian Pediatrics